Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.

Hylton N.

J Clin Oncol. 2006 Jul 10;24(20):3293-8. Review.

PMID:
16829653
2.

Dynamic contrast-enhanced magnetic resonance imaging in oncology.

Knopp MV, Giesel FL, Marcos H, von Tengg-Kobligk H, Choyke P.

Top Magn Reson Imaging. 2001 Aug;12(4):301-8. Review.

PMID:
11687716
3.

Molecular imaging of antiangiogenic agents.

Rehman S, Jayson GC.

Oncologist. 2005 Feb;10(2):92-103. Review.

4.

Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.

Padhani AR.

J Magn Reson Imaging. 2002 Oct;16(4):407-22. Review.

PMID:
12353256
5.

Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging.

Padhani AR, Leach MO.

Abdom Imaging. 2005 May-Jun;30(3):324-41. Review.

PMID:
15688112
6.

MR imaging of tumor microcirculation: promise for the new millennium.

Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge VM, Mayr N.

J Magn Reson Imaging. 1999 Dec;10(6):903-7.

PMID:
10581502
7.
8.

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.

Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM.

Magn Reson Imaging. 2007 Apr;25(3):319-27. Epub 2007 Feb 5.

PMID:
17371720
9.

Fundamentals of quantitative dynamic contrast-enhanced MR imaging.

Paldino MJ, Barboriak DP.

Magn Reson Imaging Clin N Am. 2009 May;17(2):277-89. doi: 10.1016/j.mric.2009.01.007. Review.

PMID:
19406359
11.

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM.

J Clin Oncol. 2008 Oct 1;26(28):4572-8. doi: 10.1200/JCO.2007.15.5655.

12.

Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging.

Faccioli N, Marzola P, Boschi F, Sbarbati A, D'Onofrio M, Pozzi Mucelli R.

Radiol Med. 2007 Apr;112(3):319-28. Epub 2007 Apr 20. English, Italian.

PMID:
17440699
13.

Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.

Choyke PL, Dwyer AJ, Knopp MV.

J Magn Reson Imaging. 2003 May;17(5):509-20. Review.

PMID:
12720260
14.

Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.

Muruganandham M, Lupu M, Dyke JP, Matei C, Linn M, Packman K, Kolinsky K, Higgins B, Koutcher JA.

Mol Cancer Ther. 2006 Aug;5(8):1950-7.

15.

Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.

Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Ménard C, Warde P, Trachtenberg J, Lockwood G, Milosevic M.

Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):425-30. Epub 2007 Sep 19.

PMID:
17881141
16.

Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report.

Evelhoch J, Garwood M, Vigneron D, Knopp M, Sullivan D, Menkens A, Clarke L, Liu G.

Cancer Res. 2005 Aug 15;65(16):7041-4.

17.

Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate.

Bonekamp D, Macura KJ.

Top Magn Reson Imaging. 2008 Dec;19(6):273-84. doi: 10.1097/RMR.0b013e3181aacdc2. Review.

PMID:
19512849
18.

Dynamic contrast-enhanced MRI in oncology drug development.

Cheng HL.

Curr Clin Pharmacol. 2007 May;2(2):111-22. Review.

PMID:
18690858
19.

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT Jr, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS.

J Clin Oncol. 2005 Aug 20;23(24):5464-73. Epub 2005 Jul 18.

PMID:
16027440
20.

Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.

Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, Kitagaki H, Igawa M.

Acta Radiol. 2008 Dec;49(10):1207-13. doi: 10.1080/02841850802508959.

PMID:
19031184

Supplemental Content

Support Center